Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$38.07

1.49 (4.07%)

, BMRN

BioMarin

$85.40

-0.05 (-0.06%)

09:25
10/19/16
10/19
09:25
10/19/16
09:25

Piper Jaffray biopharma analysts hold an analyst/industry conference call

Biopharmaceuticals Analysts Schimmer and Breazzano discuss the current management and treatment of hemophilia, potential for new treatment options, including gene therapy, bispecific antibodies, RNAi, etc., on an Analyst/Industry conference call to be held on October 19 at 10 am.

ALNY

Alnylam

$38.07

1.49 (4.07%)

BMRN

BioMarin

$85.40

-0.05 (-0.06%)

DMTX

Dimension Therapeutics

$6.78

0.62 (10.06%)

ONCE

Spark Therapeutics

$53.91

0.28 (0.52%)

QURE

uniQure

$7.25

0.07 (0.97%)

RGNX

REGENXBIO

$16.15

0.25 (1.57%)

RHHBY

Roche

$29.46

0.11 (0.37%)

SGMO

Sangamo

$3.90

0.05 (1.30%)

  • 19

    Oct

  • 19

    Oct

  • 26

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 10

    Nov

  • 29

    Nov

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

ALNY Alnylam
$38.07

1.49 (4.07%)

10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Alnylam price target lowered to $100 from $150 at Cowen
Cowen analyst Ritu Baral noted Alnylam announced the discontinuation of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy due to risk/benefit and safety signals. The analyst does not believe it signals any risk to the platform, as other programs have shown solid safety. Baral said revusiran was a minor driver so she maintained her Outperform rating and lowered her price target to $100 from $150 on Alnylam shares.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded on reduced competition, valuation at BMO Capital
As noted earlier, BMO Capital upgraded Ionis (IONS) to Outperform from Market Perform. After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, BMO Capital analyst Do Kim expects Ionis to benefit from the reduced competition. Kim recommends buying Ionis' stock on weakness today. Target to $48 from $42.
10/07/16
MSCO
10/07/16
DOWNGRADE
MSCO
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Morgan Stanley
10/07/16
MSCO
10/07/16
DOWNGRADE
Target $36
MSCO
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz downgraded Alnylam Pharmaceuticals after the company discontinued development of revusiran. The analyst removed Alnylam from its model and cut its price target to $36 from $93 on shares.
BMRN BioMarin
$85.40

-0.05 (-0.06%)

10/17/16
JANY
10/17/16
NO CHANGE
JANY
PTC's denial has negative read-through for BioMarin, says Janney Capital
Janney Capital noted that PTC Therapeutics' (PTCT) Translarna and Sarepta's (SRPT) Exondys 51 address non-overlapping DMD populations and there was an expectation of flexibility from the FDA following the conditional approval of Exondys 51. However, the FDA has denied the first appeal of the refuse to file letter regarding PTC's NDA for Translarna for the treatment of nonsense mutation DMD, which the firm said has potential negative read-through for BioMarin's (BMRN) attempt to rekindle Kyndrisa, which is a direct competitor to Sarepta's Exondys 51. The firm added that the news might positively impact reimbursement decisions for Exondys 51.
10/14/16
BARD
10/14/16
NO CHANGE
Target $115
BARD
Outperform
BioMarin hemophilia drug update encouraging, says Baird
Baird analyst Michale Ulz said he is encouraged by BioMarin's update on its Phase 1/2 study of its Hemophilia A drug, BMN-270. The analyst noted U.K. regulators approved continued enrollment in the gene-therapy study and the study was amended to allow dose optimization ahead of the Phase 2b study expected in 2017. Ulz reiterated his Outperform rating and $115 price target on BioMarin shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
DMTX Dimension Therapeutics
$6.78

0.62 (10.06%)

02/18/16
CANT
02/18/16
INITIATION
Target $10
CANT
Buy
Dimension Therapeutics initiated with a Buy at Cantor
Cantor Fitzgerald analyst Caroline Corner started Dimension Therapeutics with a Buy rating and $10 price target.
03/30/16
GSCO
03/30/16
DOWNGRADE
Target $10
GSCO
Neutral
Dimension Therapeutics downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Salveen Richter downgraded Dimension Therapeutics (DMTX) to Neutral saying other names in the sector offer better near-term opportunities. The analyst views Dimension as well-positioned in the gene therapy space, however. He lowered his price target for the shares to $10 from $12. Richter this morning also initiated SAGE Therapeutics (SAGE) with a Buy rating and Acorda Therapeutics (ACOR) with a Sell rating.
06/02/16
JEFF
06/02/16
INITIATION
Target $12
JEFF
Buy
Dimension Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Gena Wang started Dimension Therapeutics with a Buy rating and $12 price target.
06/02/16
CANT
06/02/16
NO CHANGE
Target $32
CANT
Buy
Dimension Therapeutics coverage assumed with a Buy at Cantor
Target $32.
ONCE Spark Therapeutics
$53.91

0.28 (0.52%)

09/02/16
STFL
09/02/16
INITIATION
STFL
Buy
Spark Therapeutics initiated with a Buy at Stifel
Target $73.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
QURE uniQure
$7.25

0.07 (0.97%)

06/15/16
WBTH
06/15/16
NO CHANGE
Target $35
WBTH
Buy
uniQure price target lowered to $35 from $60 at WallachBeth
WallachBeth analyst Caroline Palomeque cut her price target for uniQure to $35 after the company hosted a conference call to discuss data from its Phase I/II trial of AMT-060, its gene therapy treatment for Hemophilia B. The five-patient low-dose cohort showed that four patients improved their level of FIX activity at a mean of 5.4% of normal and that this was sustained at six months, Palomeque tells investors in a research note. She views the data as encouraging. The analyst's lowered price target reflects "overall market conditions including a contraction in the Biotech sector since 1/2016." Palomeque has a Buy rating on uniQure.
07/26/16
JANY
07/26/16
NO CHANGE
Target $26
JANY
Buy
uniQure fair value estimate lowered to $26 from $40 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay lowered his fair value estimate for uniQure to $26 from $40 on valuation. The analyst notes that uniQure's stock has been trading at levels suggesting not only its Hemophilia B program, but also the remainder of the pipeline is worth zero. However, he expects compelling risk/reward ahead of "significant" pipeline news over the next three quarters. Chattopadhyay reiterates a Buy rating on the shares.
08/04/16
HCWC
08/04/16
INITIATION
Target $21
HCWC
Buy
uniQure assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak assumed coverage of uniQure with a Buy rating and $21 price target.
08/04/16
08/04/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. LendingClub (LC) initiated with a Perform at Oppenheimer. 2. uniQure (QURE) assumed with a Buy at H.C. Wainwright. 3. Sunworks (SUNW) initiated with a Buy at Chardan. 4. CSX ( CSX), Canadian Pacific (CP), Norfolk Southern (NSC), and Union Pacific (UNP) initiated with a Hold, and Kansas City Southern (KSU) initiated with a Buy at Loop Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RGNX REGENXBIO
$16.15

0.25 (1.57%)

10/20/15
CHDN
10/20/15
INITIATION
Target $33
CHDN
Buy
Regenxbio initiated with a Buy at Chardan
Target $33.
10/20/15
10/20/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 21st Century Fox (FOXA) initiated with a Buy at Pivotal Research... AMC Networks (AMCX) initiated with a Market Perform at Cowen... Aduro Biotech (ADRO) initiated with an Outperform at Oppenheimer... CBS (CBS) initiated with a Buy at Pivotal Research... CDTi (CDTI) initiated with a Buy at Rodman & Renshaw... Callon Petroleum (CPE) initiated with a Buy at Canaccord... Cimarex Energy (XEC) initiated with a Hold at Canaccord... Cooper Tire (CTB) initiated with a Hold at Jefferies... Cubic (CUB) initiated with a Buy at BB&T... Diamond Offshore (DO) initiated with a Sell at Citi... Diamondback Energy (FANG) initiated with a Buy at Canaccord... Discovery (DISCA) initiated with a Buy at Pivotal Research... Disney (DIS) initiated with a Hold at Pivotal Research... Dorman Products (DORM) initiated with a Hold at Jefferies... Ensco (ESV) initiated with a Buy at Citi... First Data (FDC) initiated with a Positive at Susquehanna... InterOil (IOC) initiated with a Buy at Citi... Matador (MTDR) initiated with a Hold at Canaccord... Monro Muffler (MNRO) initiated with a Buy at Sterne Agee CRT... Noble Corp. (NE) initiated with a Neutral at Citi... Pacific Drilling (PACD) initiated with a Neutral at Citi... Parsley Energy (PE) initiated with a Buy at Canaccord... Pioneer Natural (PXD) initiated with a Buy at Canaccord... Pure Storage (PSTG) initiated with a Hold at Jefferies... Qorvo (QRVO) initiated with a Buy at Drexel Hamilton... RSP Permian (RSPP) initiated with a Hold at Canaccord... Regenxbio (RGNX) initiated with a Buy at Chardan... Reliance Steel (RS) initiated with a Buy at Deutsche Bank... Resonant (RESN) initiated with a Buy at Drexel Hamilton... Ring Energy (REI) initiated with a Buy at Canaccord... Rock Creek Pharmaceuticals (RCPI) initiated with a Buy at Maxim... Rowan Companies (RDC) initiated with a Neutral at Citi... Shire (SHPG) initiated with a Buy at BTIG... Skyworks (SWKS) initiated with a Buy at Drexel Hamilton... Snap-On (SNA) initiated with a Hold at Jefferies... Standard Motor (SMP) initiated with a Buy at Jefferies... Time Warner (TWX) initiated with a Buy at Pivotal Research... TowerJazz (TSEM) initiated with a Buy at Drexel Hamilton... Transocean (RIG) initiated with a Sell at Citi... Viacom (VIAB) initiated with a Buy at Pivotal Research... bluebird bio (BLUE) initiated with an Outperform at Oppenheimer.
12/30/15
CHDN
12/30/15
NO CHANGE
Target $35
CHDN
Buy
REGENXBIO news a clear positive, says Chardan
Chardan analyst Gbolahan Amusa raised his price target for REGENXBIO shares to $35 from $33 after the FDA granted Rare Pediatric Disease Designation to RGX-111, the company's investigational gene therapy product candidate for the treatment of mucopolysaccharidosis Type I. The designation could lead to a Rare Pediatric Disease Priority Review Voucher, which could be worth up to $8 per share, Amusa tells investors in a research note. The analyst keeps a Buy rating on the stock.
01/07/16
PIPR
01/07/16
NO CHANGE
Target $33
PIPR
Overweight
REGENXBIO pipeline expanding faster than expected, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said REGENXBIO's corporate updates released this morning show that its preclinical pipeline is expanding faster than he'd expected. The analyst continues to think that this year will include relevant newsflow for REGENXBIO as the company's vectors progress toward clinical development and keeps an Overweight rating on shares, but trimmed his price target to $33 from $36 to account for the company's guidance for a 2016 cash burn of $60M-$70M.
RHHBY Roche
$29.46

0.11 (0.37%)

10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
SGMO Sangamo
$3.90

0.05 (1.30%)

12/17/15
12/17/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ADP (ADP) initiated with a Neutral at Sterne Agee CRT... Accenture (ACN) initiated with a Buy at Sterne Agee CRT... Alliance Data (ADS) initiated with a Buy at Sterne Agee CRT... Axsome Therapies (AXSM) initiated with a Buy at Brean Capital... Blue Bird (BLBD) initiated with a Buy at Stifel... Burlington Stores (BURL) initiated with a Hold at BB&T... Chimerix (CMRX) initiated with a Buy at UBS... Cimarex Energy (XEC) initiated with a Buy at SunTrust... Clovis (CLVS) initiated with a Buy at Janney Capital... Cognizant (CTSH) initiated with a Neutral at Sterne Agee CRT... Container Store (TCS) initiated with a Neutral at Goldman... Cooper Companies (COO) initiated with a Neutral at Goldman... Corcept Therapeutics (CORT) initiated with a Buy at Janney Capital... Dave & Buster's (PLAY) initiated with an Outperform at BMO Capital... EPAM Systems (EPAM) initiated with a Buy at Sterne Agee CRT... FIS (FIS) initiated with a Neutral at Sterne Agee CRT... First Data (FDC) initiated with a Buy at Sterne Agee CRT... Fiserv (FISV) initiated with a Buy at Sterne Agee CRT... Frontline (FRO) initiated with a Buy at Seaport Global... Gener8 Maritime (GNRT) initiated with a Buy at Seaport Global... Genocea (GNCA) initiated with a Buy at UBS... Geron (GERN) initiated with a Buy at Janney Capital... Global Payments (GPN) initiated with a Buy at Sterne Agee CRT... Globant (GLOB) initiated with a Buy at Sterne Agee CRT... Harris (HRS) initiated with a Buy at Jefferies... Horizon Pharma (HZNP) initiated with a Buy at Goldman... Infosys (INFY) initiated with a Neutral at Sterne Agee CRT... Kate Spade (KATE) initiated with a Neutral at Goldman... Marinus Pharmaceuticals (MRNS) initiated with an Outperform at RBC Capital... MasterCard (MA) initiated with a Buy at Sterne Agee CRT... MicroVision (MVIS) initiated with a Buy at Rodman & Renshaw... Monro Muffler (MNRO) initiated with a Neutral at Goldman... Newfield Exploration (NFX) initiated with a Neutral at SunTrust... Orbital ATK (OA) initiated with a Buy at UBS... Paychex (PAYX) initiated with a Neutral at Sterne Agee CRT... Relypsa (RLYP) initiated with a Buy at H.C. Wainwright... Republic Services (RSG) initiated with an Overweight at JPMorgan... Ross Stores (ROST) initiated with a Buy at BB&T... Rubicon Project (RUBI) initiated with a Buy at Jefferies... Sangamo (SGMO) initiated with a Buy at Janney Capital... Skyworks (SWKS) initiated with a Buy at Chardan... TJX (TJX) initiated with a Buy at BB&T... TopBuild (BLD) initiated with an Overweight at Stephens... Unit Corp. (UNT) initiated with a Buy at SunTrust... Upland Software (UPLD) initiated with a Buy at Roth Capital... Virtusa (VRTU) initiated with a Neutral at Sterne Agee CRT... Visa (V) initiated with a Buy at Sterne Agee CRT... Waste Connections (WCN) initiated with an Overweight at JPMorgan... Waste Management (WM) initiated with a Neutral at JPMorgan... Williams-Sonoma (WSM) initiated with a Neutral at Guggenheim... Wipro (WIT) initiated with an Underperform at Sterne Agee CRT... vTv Therapeutics (VTVT) initiated with a Buy at Janney Capital.
03/07/16
JANY
03/07/16
NO CHANGE
Target $15
JANY
Buy
Sangamo data support expectations for IVPRP efficacy, says Janney Capital
Janney Capital analyst Roy Buchanan says that updated mouse data for Sangamo's in vivo protein replacement platform, or IVPRP, for treating MPS I and II continue to support expectations for efficacy and that the brain data is encouraging and adds additional support. The analyst notes, however, that he hasn't increased his probability of success for the program on this data, as much of it had been presented previously. Buchanan keeps a Buy rating and $15 fair value estimate on Sangamo shares.
08/04/16
JANY
08/04/16
DOWNGRADE
JANY
Neutral
Sangamo downgraded to Neutral from Buy at Janney Capital
09/06/16
WELS
09/06/16
NO CHANGE
WELS
Outperform
Wells calls Sangamo an 'attractive new investment opportunity'
After the FDA granted orphan drug designation to its Factor IX gene-editing product candidate, SB-FIX, as a treatment for hemophilia B, Wells Fargo analyst Jim Birchenough calls Sangamo BioSciences an "attractive new investment opportunity." Along with validating a commercial opportunity in hemophilia, SB-FIX could provide "even more valuable validation of targeting and coopting the albumin gene locus for gene insertion that may apply to a wide variety of genetic diseases," Birchenough tells investors in a research note. He keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

, CSCO

Cisco

$30.06

0.11 (0.37%)

18:32
12/09/16
12/09
18:32
12/09/16
18:32
Hot Stocks
Arista Networks favored in ITC initial determination on four of six patents »

Arista Networks (ANET)…

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

CSCO

Cisco

$30.06

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

TKTDY

Takata Corporation

$10.70

0.05 (0.47%)

18:22
12/09/16
12/09
18:22
12/09/16
18:22
Periodicals
U.S. DOT looks to accelerate pace of Takata air bag replacements, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DV

DeVry

$31.90

0.9 (2.90%)

18:17
12/09/16
12/09
18:17
12/09/16
18:17
Hot Stocks
Breaking Hot Stocks news story on DeVry »

International Value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

18:10
12/09/16
12/09
18:10
12/09/16
18:10
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Cornerstone OnDemand has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.12

-0.0014 (-1.17%)

18:03
12/09/16
12/09
18:03
12/09/16
18:03
Hot Stocks
NYSE MKT says CEL-SCI noncompliant with certain listing requirements »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$89.00

0.68 (0.77%)

18:01
12/09/16
12/09
18:01
12/09/16
18:01
Periodicals
Exxon CEO Tillerson emerges as top candidate for secretary of state, WSJ says »

Exxon Mobil CEO Rex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

17:58
12/09/16
12/09
17:58
12/09/16
17:58
Hot Stocks
H.B. Fuller announces restructuring, to eliminate, relocate 220 positions »

H.B. Fuller has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$287.77

-1.77 (-0.61%)

17:53
12/09/16
12/09
17:53
12/09/16
17:53
Periodicals
Biogen looks like a bargain, Barron's reports »

Biogen trades at just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$40.40

0.63 (1.58%)

17:42
12/09/16
12/09
17:42
12/09/16
17:42
Periodicals
Sanofi to lay off 20% of U.S. diabetes, cardiovascular staff, Bloomberg says »

The layoffs include parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

17:38
12/09/16
12/09
17:38
12/09/16
17:38
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Investor Praesidium said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$14.75

-0.39 (-2.58%)

17:34
12/09/16
12/09
17:34
12/09/16
17:34
Hot Stocks
Breaking Hot Stocks news story on Del Taco »

PW Acquisitions cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 09

    Dec

UNVR

Univar

$26.36

0.54 (2.09%)

, BXLT

Baxalta

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Univar names Eric Foster chief information officer »

Univar (UNVR) named Eric…

UNVR

Univar

$26.36

0.54 (2.09%)

BXLT

Baxalta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Breaking Hot Stocks news story on Parnell 

Parnell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$20.81

0.2 (0.97%)

, NVRO

Nevro

$76.38

-1.88 (-2.40%)

17:24
12/09/16
12/09
17:24
12/09/16
17:24
Hot Stocks
Boston Scientific files patent infringement suit against Nevro »

Nevro (NVRO) announced…

BSX

Boston Scientific

$20.81

0.2 (0.97%)

NVRO

Nevro

$76.38

-1.88 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RTN

Raytheon

$146.30

0.14 (0.10%)

17:21
12/09/16
12/09
17:21
12/09/16
17:21
Hot Stocks
Raytheon awarded $101.9M government contract »

Raytheon Co., Goleta,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$8.77

-0.16 (-1.79%)

17:18
12/09/16
12/09
17:18
12/09/16
17:18
Hot Stocks
CEMEX receives subpoena from SEC regarding Foreign Corrupt Practices Act »

On December 9, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDEX

PRO-DEX

$4.48

0.034 (0.76%)

17:06
12/09/16
12/09
17:06
12/09/16
17:06
Syndicate
Breaking Syndicate news story on PRO-DEX »

PRO-DEX files $25M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFBX

Peoples Financial

$14.50

-0.5 (-3.33%)

17:02
12/09/16
12/09
17:02
12/09/16
17:02
Hot Stocks
Breaking Hot Stocks news story on Peoples Financial »

Jeffrey L. Gendell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUIK

QuickLogic

$0.94

-0.0163 (-1.71%)

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Syndicate
Breaking Syndicate news story on QuickLogic »

QuickLogic files $40M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STRZA

Starz

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Hot Stocks
Breaking Hot Stocks news story on Starz »

Elliott Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEL

Belmond

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Syndicate
Breaking Syndicate news story on Belmond »

Belmond files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Hot Stocks
Breaking Hot Stocks news story on Parnell »

Parnell trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, SHAK

Shake Shack

$38.08

0.82 (2.20%)

16:50
12/09/16
12/09
16:50
12/09/16
16:50
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Shake Shack »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

SHAK

Shake Shack

$38.08

0.82 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, LXFT

Luxoft

$54.40

-1.8 (-3.20%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Luxoft »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

LXFT

Luxoft

$54.40

-1.8 (-3.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
H.B. Fuller announces restructuring plan »

On December 7, H.B.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.